In a move marking a significant expansion in the biopharmaceutical sector, Eli Lilly and Company (Lilly) has successfully completed the acquisition of Versanis Bio, a clinical-stage biopharmaceutical player founded by Aditum Bio in 2021. This strategic acquisition sets the stage for Lilly to delve deeper into pioneering treatments for cardiometabolic diseases, including obesity. Central to […]
Eli Lilly and Company (Lilly) has finalized its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE) for $2.4 billion, bolstering its immunology portfolio with the inclusion of the latter’s innovative oral therapeutic candidates. This acquisition, made in an all-cash transaction, will incorporate DICE Therapeutics’ breakthrough DELSCAPE technology platform, designed for developing advanced oral therapeutic candidates. Specifically, […]
Eli Lilly and Company (NYSE: LLY) unveiled their Q2 2023 financials, showcasing a 28% revenue enhancement, predominantly driven by volume growth from Mounjaro, Verzenio, Jardiance, and Taltz. The revenue spike includes a notable $579.0 million from the Baqsimi rights sale. Excluding this sale and 2022’s COVID-19 antibodies, the Q2 2023 revenue surged by 22%. Key […]
Eli Lilly and Company (NYSE: LLY) has unveiled top-line results from the LIBRETTO-431 study, which focused on the assessment of Retevmo against platinum-based chemotherapy plus pemetrexed in patients diagnosed with RET fusion-positive advanced non-small cell lung cancer (NSCLC). The findings showcased a notable improvement in progression-free survival (PFS), a primary objective of the study. Study […]
Eli Lilly and Company has unveiled the results of two Phase 3 tirzepatide studies (SURMOUNT-3 and SURMOUNT-4) targeting adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes. Both studies successfully met all primary and key secondary objectives, showcasing the effectiveness of tirzepatide over a placebo. The results saw participants on tirzepatide, after […]
Eli Lilly and Company (Lilly) revealed complete results from its Phase 3 TRAILBLAZER-ALZ 2 study at the 2023 Alzheimer’s Association International Conference (AAIC), indicating that the experimental drug, donanemab, significantly slowed the cognitive and functional decline in patients with early symptomatic Alzheimer’s disease. The data was simultaneously published in the Journal of the American Medical […]
Sangamo Therapeutics, a genomic medicine company, has entered an evaluation and option agreement with Prevail Therapeutics, an Eli Lilly subsidiary, for novel engineered capsids. The deal allows Prevail Therapeutics to evaluate Sangamo Therapeutics’ proprietary adeno-associated virus (AAV) capsids for potential use in various neurological targets. The capsids, produced through Sangamo Therapeutics’ AAV capsid engineering platform […]
American pharma giant Eli Lilly and Company (Lilly) and Versanis Bio have announced a definitive agreement in which the former will acquire the privately-held clinical-stage biopharmaceutical company. Founded by Aditum Bio in 2021, Versanis Bio is focused on the development of new treatments for cardiometabolic diseases. The acquisition will see Versanis Bio’s leading asset, bimagrumab, […]
Lilly’s breast cancer drug, abemaciclib given in combination with fulvestrant has met its primary endpoint of progression-free survival (PFS) in a phase 3 breast cancer trial.
Indianapolis-based pharmaceutical giant Lilly has announced positive outcomes from its phase 3 clinical trial, MONARCH 2, involving its innovative breast cancer treatment, abemaciclib, in combination with fulvestrant. This trial marks a significant advancement in the treatment of hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Groundbreaking Results in Cancer Treatment The […]